Veru Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Veru şirketinin kazançları yıllık ortalama -44.3% oranında azalırken, Personal Products sektörünün kazançları yıllık 11.7% oranında artan oldu. Gelirler yıllık ortalama 14.2% oranında azalan oldu.

Anahtar bilgiler

-44.3%

Kazanç büyüme oranı

-39.0%

EPS büyüme oranı

Personal Products Sektör Büyümesi	20.9%
Gelir büyüme oranı	-14.2%
Özkaynak getirisi	-99.4%
Net Marj	-265.4%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is Veru (NASDAQ:VERU) A Risky Investment?

Aug 07

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Jul 17

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 31

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Veru eligible for expedited review in U.K. for COVID-19 therapy

Jul 25

Gelir ve Gider Dağılımı

Veru nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:VERU Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	14	-37	30	40
31 Mar 24	13	-39	34	17
31 Dec 23	16	-63	51	32
30 Sep 23	16	-93	52	51
30 Jun 23	15	-126	63	48
31 Mar 23	21	-136	63	84
31 Dec 22	28	-116	46	81
30 Sep 22	39	-84	43	71
30 Jun 22	52	-47	31	52
31 Mar 22	60	-28	26	45
31 Dec 21	61	-16	23	37
30 Sep 21	61	7	21	33
30 Jun 21	57	0	19	28
31 Mar 21	50	0	17	21
31 Dec 20	47	2	16	17
30 Sep 20	43	-19	15	17
30 Jun 20	40	-10	15	17
31 Mar 20	39	-10	15	18
31 Dec 19	36	-13	15	17
30 Sep 19	32	-12	14	14
30 Jun 19	28	-17	15	13
31 Mar 19	24	-22	15	12
31 Dec 18	20	-22	15	11
30 Sep 18	16	-24	15	11
30 Jun 18	14	-21	14	9
31 Mar 18	13	-14	13	6
31 Dec 17	13	-11	12	5
30 Sep 17	14	-9	12	3
30 Jun 17	14	-6	10	2
31 Mar 17	15	-4	8	1
31 Dec 16	17	-3	8	0
30 Sep 16	22	0	9	0
30 Jun 16	26	3	10	0
31 Mar 16	28	3	12	0
31 Dec 15	34	5	13	0
30 Sep 15	33	4	12	0
30 Jun 15	31	3	12	0
31 Mar 15	31	3	11	0
31 Dec 14	24	2	9	0
30 Sep 14	24	2	9	0
30 Jun 14	24	10	6	0
31 Mar 14	23	9	7	0
31 Dec 13	28	12	7	0

Kaliteli Kazançlar: VERU şu anda kârlı değil.

Büyüyen Kar Marjı: VERU şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VERU kârlı değildir ve zararlar son 5 yılda yılda 44.3% oranında artmıştır.

Büyüme Hızlandırma: VERU 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: VERU kârlı olmadığından, geçmiş yıl kazanç büyümesinin Personal Products sektörüyle ( 22.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: VERU hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -99.42% ) sahiptir.

Veru Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 16% to US$4.00

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Veru (NASDAQ:VERU) A Risky Investment?

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

New major risk - Financial position

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold US$247k worth of stock

Consensus revenue estimates increase by 65%, EPS downgraded

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Consensus revenue estimates decrease by 32%, EPS upgraded

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Consensus revenue estimates decrease by 44%, EPS upgraded

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Consensus revenue estimates increase by 12%

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Consensus revenue estimates fall by 60%

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$25.60

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Price target decreased to US$25.60

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed

Veru: A Good Combination Of A Stable Business And Growth Opportunities